Application No.: 10/010,055

Attorney Docket No.: 03678.0023.CNUS04

REMARKS

Provisional Double Patenting Rejection

Claims 1-11 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as allegedly being unpatentable over Claims 1-2, 4, and 7-15 of copending Application No. 10/041,826.

The present application is directed to a method of stimulating tear secretion and mucin production in eyes. The '826 application is directed to a method of enhancing drainage of the lacrimal system. A method of stimulating tear secretion is not an obvious variation of a method of enhancing drainage of the lacrimal system. The two methods involve different part of tissues, have opposite mechanisms and different functions, and achieve different end results.

Applicants do not agree with the rejection. However, a Terminal Disclaimer was already submitted in the '826 Application over the instant application on November 1, 2004. A copy of the Terminal Disclaimer is enclosed herewith. Therefore, the provisional double patenting rejection should be withdrawn.

CONCLUSION

Applicants believe that the application is in good and proper condition for allowance. Early notification of allowance is earnestly solicited. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 463-8181.

Respectfully submitted,

Date: January 27, 2005

Viola T. Kung (Reg. No. 41,131)

Enclosure: copy of Terminal Disclaimer

HOWREY SIMON ARNOLD & WHITE, LLP

2941 Fairview Park Drive Box 7

DUX / E-11- C1

Falls Church, VA 22042

Ph. (650) 463-8181

Fax (650) 463-8400

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. AL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION

Docket Number (Optional) 03678.0023.CNUS03

In re Application of: Benjamin R. YERXA, et al.

Application No.: 10/041,826

Filed: January 3, 2002



FOI. METHOD OF ENHANCING DRAINAGE OF LACRIMAL SYSTEM WITH PURINERGIC RECEPTOR AGONISTS

The owner*, Inspire Pharmaceuticals, of 100% percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/010,055, filed on 11/09/01, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that: any such patent: granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner

terminated prior to	the expiration of its full statutory term	as shortened by any terminal	disclaimer filed prior to its grant.
Check either box 1	or 2 below, if appropriate.		
1. For submetc.), the	For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.		
belief are believed made are punisha	to be true; and further that these st	atements were made with th under Section 1001 of Title	re true and that all statements made on information and e knowledge that willful false statements and the like so 18 of the United States Code and that such willful false.
2. The under	ersigned is an attorney or agent of record	i. Reg. No. <u>41,131</u>	
	Unit 1	P	November 1, 2004
		ブSignature	Date
	Viola T. Kung		
		Typed or printed	
			(650) 463-8181
			Telephone Number
Terminal di	isdaimer fee under 37 CFR 1 .20(d) is inc	luded.	
	was a second of the second of	may basama mublic Cr	odit card information should not
	WARNING: Information on this forbe included on this form. Provide	arm may become public. Cr de credit card information a	and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).

Form PTO/SB/96 may be used for making this statement. See MPEP § 324.